Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ACP3 | P15309 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL143128 | 0.81 | MTNR1A (0.47) | MTNR1ANQO2GPR84TDP1MCL1 | |
| SCHEMBL2106557 | 0.81 | MTNR1A (0.42) | MTNR1ANQO2GPR84TDP1MCL1 | |
| SCHEMBL9216856 | 0.80 | CYP1A2 (0.48) | MTNR1ANQO2GPR84TDP1MCL1 | |
| SCHEMBL143959 | 0.79 | TDP1 (0.47) | MTNR1ANQO2TDP1CYP1A2CYP2C19 | |
| SCHEMBL9800436 | 0.78 | CYP1A2 (0.58) | MTNR1ANQO2GPR84TDP1MCL1 | |
| SCHEMBL5830948 | 0.78 | GPR84 (0.59) | MTNR1ANQO2GPR84TDP1MCL1 | |
| SCHEMBL5609954 | 0.77 | SIGMAR1 (0.50) | MTNR1ANQO2GPR84CYP1A2CYP2C19 | |
| SCHEMBL5958314 | 0.77 | CYP1A2 (0.46) | MTNR1ANQO2GPR84TDP1MCL1 | |
| SCHEMBL143127 | 0.77 | MTNR1A (0.46) | MTNR1ANQO2GPR84TDP1MCL1 | |
| SCHEMBL6028071 | 0.77 | TLR8 (0.50) | MTNR1ANQO2GPR84TDP1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 536 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240084308-A1 | FIBROTIC TREATMENT | MONASH UNIVERSITY (AU) | 2024-03-14 | — | — | US | disclosed |
| US-20240034845-A1 | POLYMER PARTICLES | QUEENSLAND UNIVERSITY OF TECHNOLOGY (AU) | 2024-02-01 | — | — | US | disclosed |
| EP-3384549-B1 | SODIUM-ION ELECTROLYTE COMPOSITION | UNIV DEAKIN (AU) | 2024-01-17 | — | — | EP | disclosed |
| US-11834663-B2 | Fibrotic treatment | MONASH UNIVERSITY (AU) | 2023-12-05 | — | — | US | disclosed |
| US-20230348674-A1 | HYDROGELS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2023-11-02 | — | — | US | disclosed |
| CN-113939544-B | non-core-shell polymer particles | 悉尼大学 | 2023-08-22 | — | — | CN | disclosed |
| CN-116615468-A | Polymer particles | 昆士兰科技大学 | 2023-08-18 | — | — | CN | disclosed |
| EP-4225811-A1 | POLYMER PARTICLES | Queensland University Of Technology (AU) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023121483-A1 | IMMUNOSTIMULATORY COMPOSITIONS | VICTORIA LINK LIMITED (NZ) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023102600-A1 | SYNTHESIS OF AMPHIPHILIC BLOCK COPOLYMERS AND POLYMERIC NANOFIBERS PRODUCED THEREFROM | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2023-06-15 | — | — | WO | disclosed |
| EP-0531901-A2 | Condensed pyrazole derivatives with interleukin-1 and tumour necrosis factor inhibitory activity | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-17 | — | — | EP | disclosed |
| WO-1992018483-A1 | QUINOLINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-29 | — | — | WO | disclosed |
| US-5155101-A | Tricyclic compounds | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| EP-0498069-A2 | New use of peptide derivative | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-08-12 | — | — | EP | disclosed |
| WO-1992012154-A1 | IMIDAZOTRIAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-07-23 | — | — | WO | disclosed |
| WO-1992003438-A1 | TRICYCLIC BENZODIAZEPINE DERIVATES THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-03-05 | — | — | WO | disclosed |
| WO-1992002513-A1 | HETEROCYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-02-20 | — | — | WO | disclosed |
| US-4981847-A | Tricyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-01-01 | — | — | US | disclosed |
| EP-0360079-A1 | Tricyclic compounds, processes for their preparation and pharmaceutical compositions comprising them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-03-28 | — | — | EP | disclosed |
| EP-0336230-A2 | Cyclic peptide antagonists of Substance P and Substance K | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834663-B2 | Fibrotic treatment | MMP1, ENPEP, RNPEP | MTNR1A 1398/4885NQO2 3834/4885GPR84 1302/4885 |
| US-20230348674-A1 | HYDROGELS | PHYKPL, TST, PHOSPHO1 | MTNR1A 4090/4885NQO2 2360/4885GPR84 1873/4885 |
| US-20240084308-A1 | FIBROTIC TREATMENT | MMP1, ENPEP, RNPEP | MTNR1A 1398/4885NQO2 3834/4885GPR84 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.